Wu Lab - Selected publications
Original research articles
Court KA, Hatakeyama H, Wu SY, et al. HSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer. Molecular Cancer Therapeutics 2017, 16(5):966-976.
Wu, S.Y., Rupaimoole, R., Shen, F., et al. A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer. Nature Communications 2016, 7:111169.
Hatakeyama, H., Wu, S.Y., Lyons, Y.A., et al. Role of CTGF in sensitivity to hyperthermia in ovarian and uterine cancers. Cell Reports 2016, 17(6):1621-31.
Miyake TM, Pradeep S, Wu SY, et al. XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. Clinical Cancer Research 2015, 21(14):3286-97.
Wu, S.Y., Yang, X.B., Gharpure, K., et al. 2’-OMe-phosphorodithioate modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nature Communications 2014, 5, 3459.
Rupaimoole, R., Wu, S.Y., Pradeep, S., et al. Hypoxia mediated downregulation of miRNA biogenesis leads to increased tumor progression. Nature Communications 2014, 5:5202.
Pradeep, S., Kim, S.W., Wu, S.Y., et al. Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell 2014, 26(1):77-91.
Pecot, C.V., Wu, S.Y., Bellister, S., et al. Therapeutic Silencing of KRAS using Systemically Delivered siRNAs. Molecular Cancer Therapeutics 2014, 13(12):2876-85.
Wu, S.Y., Chang, H.I., Burgess, M., et al. Vaginal delivery of siRNA using a novel PEGylated lipoplex-entrapped alginate scaffold system. Journal of Controlled Release 2011, 155(3):418-26.
Wu, S.Y., Singhania, A., Burgess, M., et al. Systemic delivery of E6/7 siRNA using novel lipidic particles and its application with cisplatin in cervical cancer mouse models. Gene Therapy 2011, 18(1): 14-22.
Singhania, A.*, Wu, S.Y.*, McMillan, N.A.J. Effective delivery of PEGylated siRNA-containing lipoplexes to extraperitoneal tumours following intraperitoneal administration. Journal of Drug Delivery 2011, e192562.
*These authors contributed equally to the work.
Wu, S.Y., Putral, L.N., Liang M., et al. Development of a novel method for formulating stable siRNA-loaded lipid particles for in vivo use. Pharmaceutical Research 2009, 26(3):512-22.
Wu, S., Campbell, C., Koda, Y., et al. Investigation of the route of absorption of lipid and sugar modified Leu-enkephalin analogues and their enzymatic stability using the Caco-2 cell monolayer system. Medicinal Chemistry 2006, 2(2):203-11.
Review articles
Yang M, Wu, SY. The advances and challenges in utilizing exosomes for delivering cancer therapeutics. Front Pharmacol. 2018, 9:735.
Lyons, Y., Wu, S.Y., Overwijk, W.W., et al. Immune cell profiling in cancer: molecular approaches to cell-specific identification. NPJ Precision Oncology 2017, 1:Article 26.
Gharpure, K., Wu, S.Y., Li, C., et al. Nanotechnology: Future of oncotherapy. Clinical Cancer Research 2015, 21(14):3121-30.
Wu, S.Y.; Lopez-Berestein, G.; Calin, G.A.; et al. RNAi therapeutics: Drugging the undruggable. Science Translational Medicine 2014, 6:240ps7.
Hua, S.; Wu, S.Y. The use of lipid-based nanocarriers for targeted pain therapies. Frontiers in Neuropharmacology 2013, 4: 143.
Wu, S.Y. and McMillan N.A.J. Lipidic systems for in vivo siRNA delivery. American Association of Pharmaceutical Scientists Journal 2009, 11(4):639-52.
Editorials/Commentary/Book Chapters
Hatakeyama, H., Wu, S.Y., Mangala, L.S., et al. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models. Methods Mol Biol 2016,1402:189-97.
McCaskill, J.L., Wu, S., Khairuddin, N., et al. Lowering the siRNA delivery barrier: Alginate Scaffolds and Immune stimulation. In: Peer D, editor. Nanotechnology for delivery of Therapeutic Nucleic Acids. Pan Stanford Publishing Pte. Ltd. pp. 193-216 (2013).
Wu, S.Y. Cancer therapy hits its target. Australasian Science, 2010 April, p28-30.